The U.S. Food and Drug Administration has approved an Abbreviated New Drug Application (ANDA) numbered ANDA076850 for a terconazole vaginal suppository.
The product, marketed by Fougera Pharms, is a 80 mg terconazole suppository intended for vaginal administration. The submission was an original (ORIG) filing and received approval on July 12, 2006.
FDA records indicate the product’s marketing status is listed as discontinued.
規制動向2026年9月22日•1分で読めます
FDA Approves ANDA076850 for Terconazole Vaginal Suppository
FDA granted approval (ANDA076850) for Fougera Pharms' terconazole 80 mg vaginal suppository, now listed as discontinued.
PharmaCountryチームがまとめました · 出典： FDA.gov
評価
(0)
(0)
(0)
(0)
(0)
評価を残す